You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 康哲藥業三連升累漲逾11% 地西泮鼻腔噴霧劑獲美國FDA上市批准
格隆匯 01-14 11:27
格隆匯1月14日丨康哲藥業(0867.HK)今日續漲,暫三連升累漲逾11%,現報11.18港元,漲5.47%,暫成交5654萬港元,最新總市值277億港元。康哲藥業昨晚發公告稱,美國FDA已批准其產品VALTOCO(地西泮鼻腔噴霧劑)作為一種急性治療藥物,用於治療六歲及以上癲癇患者的間歇性、刻板性癲癇頻繁發作活動。另外,集團已於近期獲得了中國藥監局對地西泮鼻噴霧劑的臨牀試驗通知書。此外據悉,康哲藥業曾在12月初發公告稱擬攜手劍橋大學等,對英國生物技術和生命科學領域進行投資。公司的投資將給公司在未來提供獲得被投資公司所研發產品在大中華地區權利的機會。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account